Post Marketing Trial (Phase IV) on the Safety, Tolerability And Efficacy of Eribulin Mesylate in Treating Patients with Locally Advanced or Metastatic Breast Cancer
Phase of Trial: Phase IV
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 26 Nov 2019 Status changed from active, no longer recruiting to completed.
- 08 Mar 2019 Planned End Date changed from 1 Jun 2019 to 1 Nov 2019.
- 08 Mar 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Aug 2019.